The estimated Net Worth of Brian K Halak is at least $12.3 Milion dollars as of 2 November 2018. Brian Halak owns over 335,000 units of Alimera Sciences stock worth over $105,900 and over the last 18 years he sold ALIM stock worth over $12,173,888. In addition, he makes $0 as Independent Director at Alimera Sciences.
Brian has made over 7 trades of the Alimera Sciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 335,000 units of ALIM stock worth $4,465,550 on 2 November 2018.
The largest trade he's ever made was buying 3,500,000 units of Alimera Sciences stock on 16 September 2011 worth over $7,000,000. On average, Brian trades about 190,188 units every 69 days since 2007. As of 2 November 2018 he still owns at least 19,150 units of Alimera Sciences stock.
You can see the complete history of Brian Halak stock trades at the bottom of the page.
Dr. Brian K. Halak Ph.D. serves as Independent Director of the Company. Dr. Halak has been a member of the Board since 2004. Dr. Halak joined Domain Associates, L.L.C. in 2001 and has served as a Partner of Domain Associates, L.L.C. since 2006. In this capacity, Dr. Halak has invested in over a dozen companies, three of which he helped create. He served as the CEO of one of the companies he created, WindMIL Therapeutics, from October 2015 through January 2019 and through two rounds of financing. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst at Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak served as an analyst at Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania. The Board believes that Dr. Halak should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to our company in recent years, his experience as CEO of a company and his service on the board of directors of more than 10 emerging companies in the life sciences industry in the past 10 years. These companies include Dicerna Pharmaceuticals, Inc., which completed a public offering on Nasdaq in 2014, Vanda Pharmaceuticals, Inc., a public company listed on Nasdaq, and Esprit Pharma, Inc., a company Allergan acquired in 2007.
Brian Halak is 48, he's been the Independent Director of Alimera Sciences since 2004. There are 14 older and 1 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.
Brian's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, ALPHARETTA, GA, 30005.
Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo a Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Alimera Sciences executives and other stock owners filed with the SEC include: